Shots:
- Hinge Bio & Kyorin have entered into a collaboration & license agreement to develop HB2198 in Japan for various autoimmune diseases, starting with systemic lupus erythematosus (SLE), which is expected to enter trials by H2’25
- As per the deal, Hinge will lead global HB2198 development & receive $10M upfront, ~$95M in SLE milestones, plus additional payments for other indications, incl. contingent R&D investment, tiered sales royalties, & a portion of investment to global development
- In contrast, Kyorin will fund development, regulatory, marketing & commercialization activities in Japan, & support global efforts. An established JSC will guide development across various B cell mediated autoimmune disorders
Ref: Hinge Bio| Image: Hinge Bio and Kyorin | Press Release
Related News:- Health Hope Pharma Collaborates with Gilead Sciences to Advance Encequidar in Virology
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
